{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:42:11Z","timestamp":1758588131387,"version":"3.44.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T00:00:00Z","timestamp":1707177600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation Proceedings"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.transproceed.2023.12.021","type":"journal-article","created":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T07:28:57Z","timestamp":1707550137000},"page":"409-415","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Navigating the Complexity of Chronic Graft-vs-Host Disease: Canadian Insights into Real-World Treatment Sequencing"],"prefix":"10.1016","volume":"56","author":[{"given":"Dennis","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minakshi","family":"Taparia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erika","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meghan","family":"Mcgee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tazmin","family":"Merali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.transproceed.2023.12.021_bib0001","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/S0140-6736(09)60237-3","article-title":"Graft-versus-host disease","volume":"373","author":"Ferrara","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.transproceed.2023.12.021_bib0002","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood-2016-06-686618","article-title":"Chronic graft-versus-host disease: biological insights from preclinical and clinical studies","volume":"129","author":"MacDonald","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.transproceed.2023.12.021_bib0003","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.transproceed.2023.12.021_bib0004","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1365-2141.2004.04945.x","article-title":"Chronic graft versus host disease","volume":"125","author":"Higman","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.transproceed.2023.12.021_bib0005","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.bbmt.2014.10.021","article-title":"Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research","volume":"21","author":"Arai","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"year":"2020","series-title":"2020 Annual Report","key":"10.1016\/j.transproceed.2023.12.021_bib0006"},{"key":"10.1016\/j.transproceed.2023.12.021_bib0007","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.jtct.2021.06.013","article-title":"Recognition of hematopoietic stem cell transplantation and cellular therapy expertise to promote care accessibility: a formally credentialed area of focused competence in Canada","volume":"27","author":"Lachance","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.transproceed.2023.12.021_bib0008","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1182\/blood.V98.6.1695","article-title":"Chronic graft-versus-host disease after allogeneic blood stem cell transplantation","volume":"98","author":"Przepiorka","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.transproceed.2023.12.021_bib0009","doi-asserted-by":"crossref","first-page":"4705","DOI":"10.1182\/blood.V90.12.4705","article-title":"Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease","volume":"90","author":"Storek","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.transproceed.2023.12.021_bib0010","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1182\/blood-2010-08-302109","article-title":"Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria","volume":"117","author":"Flowers","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.transproceed.2023.12.021_bib0011","doi-asserted-by":"crossref","first-page":"707.e1","DOI":"10.1016\/j.jtct.2022.04.014","article-title":"Healthcare resource utilization and costs of steroid-associated complications in patients with graft-versus-host disease","volume":"28","author":"Bell","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.transproceed.2023.12.021_bib0012","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1182\/blood-2014-08-551994","article-title":"How we treat chronic graft-versus-host disease","volume":"125","author":"Flowers","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.transproceed.2023.12.021_bib0013","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1016\/S2352-3026(19)30256-X","article-title":"Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation","volume":"7","author":"Penack","year":"2020","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.transproceed.2023.12.021_bib0014","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1182\/blood.2021014448","article-title":"Three US Food and Drug Administration\u2013approved therapies for chronic GVHD","volume":"139","author":"Zeiser","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.transproceed.2023.12.021_bib0016","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1182\/blood-2014-03-563544","article-title":"Failure-free survival after initial systemic treatment of chronic graft-versus-host disease","volume":"124","author":"Inamoto","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.transproceed.2023.12.021_bib0017","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.bbmt.2017.10.042","article-title":"Success of immunosuppressive treatments in patients with chronic graft-versus-host disease","volume":"24","author":"Lee","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.transproceed.2023.12.021_bib0018","first-page":"60","article-title":"A critical appraisal of extracorporeal photopheresis as a treatment modality for acute and chronic graft-versus-host disease","volume":"5","author":"Rafei","year":"2017","journal-title":"BioMed"},{"key":"10.1016\/j.transproceed.2023.12.021_bib0019","doi-asserted-by":"crossref","first-page":"5098","DOI":"10.1182\/blood-2012-10-464198","article-title":"Incidence, risk factors, and outcomes of sclerosis in patients with chronic graft-versus-host disease","volume":"121","author":"Inamoto","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.transproceed.2023.12.021_bib0020","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.1182\/blood-2011-04-350249","article-title":"Sclerotic-type chronic GVHD of the skin: clinical risk factors, laboratory markers, and burden of disease","volume":"118","author":"Martires","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.transproceed.2023.12.021_bib0021","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1038\/sj.bmt.1702429","article-title":"Non-infectious lung complications are closely associated with chronic graft-versus-host disease: a single center study of incidence, risk factors and outcome","volume":"25","author":"Duncker","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.transproceed.2023.12.021_bib0022","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2033122","article-title":"Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease","volume":"385","author":"Zeiser","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transproceed.2023.12.021_bib0023","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1182\/blood-2017-07-793786","article-title":"Ibrutinib for chronic graft-versus-host disease after failure of prior therapy","volume":"130","author":"Miklos","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.transproceed.2023.12.021_bib0024","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1200\/JCO.22.00509","article-title":"Ibrutinib for first-line treatment of chronic graft-versus-host disease: results from the randomized Phase III iNTEGRATE Study","volume":"41","author":"Miklos","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.transproceed.2023.12.021_bib0025","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1200\/JCO.20.02754","article-title":"ROCK2 inhibition with belumosudil (KD025) for the treatment of chronic graft-versus-host disease","volume":"39","author":"Jagasia","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.transproceed.2023.12.021_bib0026","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1182\/blood.2021012021","article-title":"Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study","volume":"138","author":"Cutler","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.transproceed.2023.12.021_bib0027","doi-asserted-by":"crossref","first-page":"6263","DOI":"10.1182\/bloodadvances.2022008095","article-title":"Clinical response to belumosudil in bronchiolitis obliterans syndrome: a combined analysis from 2 prospective trials","volume":"6","author":"DeFilipp","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.transproceed.2023.12.021_bib0028","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1080\/13696998.2022.2087408","article-title":"Budget impact analysis of belumosudil for chronic graft-versus-host disease treatment in the United States","volume":"25","author":"Bachier","year":"2022","journal-title":"J Med Econ"},{"key":"10.1016\/j.transproceed.2023.12.021_bib0029","unstructured":"Cell Therapy Transplant Canada: blood and marrow transplant centres. <https:\/\/www.cttcanada.org\/page\/BMTCentres> [accessed 01.06.23]."}],"container-title":["Transplantation Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134524000782?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134524000782?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T21:47:47Z","timestamp":1758577667000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041134524000782"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S0041134524000782"],"URL":"https:\/\/doi.org\/10.1016\/j.transproceed.2023.12.021","relation":{},"ISSN":["0041-1345"],"issn-type":[{"type":"print","value":"0041-1345"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Navigating the Complexity of Chronic Graft-vs-Host Disease: Canadian Insights into Real-World Treatment Sequencing","name":"articletitle","label":"Article Title"},{"value":"Transplantation Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transproceed.2023.12.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}